

US Family Health Plan Prior Authorization Request Form for Ensifentrine (Ohtuvayre)

To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) US Family Health Plan Pharmacy Program. US Family Health Plan is a TRICARE contractor for DoD.

The completed form may be faxed to 855-273-5735

OR

The patient may attach the completed form to the prescription and **mail** it to:

Attn: Pharmacy, 77 Warren St, Brighton, MA 02135

QUESTIONS? Call 1-877-880-7007

Initial approvals expire after twelve months, renewal approvals are indefinite. For renewal of therapy an initial Tricare prior authorization approval is required.

Step 1 Please complete patient and physician information (please print):

1	Patient Name: _____	Physician Name: _____
	Address: _____	Address: _____
	Sponsor ID #: _____	Phone #: _____
	Date of Birth: _____	Secure Fax #: _____

Step 2 Please complete the clinical assessment:

2	1. Has the patient received this medication under the TRICARE benefit in the last 6 months? Please choose "No" if the patient did not previously have a TRICARE approved PA for Ohtuvayre.	<input type="checkbox"/> Yes (subject to verification) Proceed to question 2	<input type="checkbox"/> No Proceed to question 3
	2. Has the patient's disease severity improved and stabilized to warrant continued therapy?	<input type="checkbox"/> Yes Sign and date below	<input type="checkbox"/> No STOP Coverage not approved
	3. Is the patient 18 years of age or older?	<input type="checkbox"/> Yes Proceed to question 4	<input type="checkbox"/> No STOP Coverage not approved
	4. Is the requested medication prescribed by or in consultation with a pulmonologist?	<input type="checkbox"/> Yes Proceed to question 5	<input type="checkbox"/> No STOP Coverage not approved
	5. What is the indication or diagnosis?	<input type="checkbox"/> Chronic obstructive pulmonary disease (COPD) - Proceed to question 6 <input type="checkbox"/> Other diagnosis – STOP Coverage not approved	
	6. Does the patient have moderate to severe COPD airflow obstruction as demonstrated by FEV1 (forced expiratory volume 1 second) that is between 30 to 80% of the predicted value?	<input type="checkbox"/> Yes Proceed to question 7	<input type="checkbox"/> No STOP Coverage not approved

<p>7. Has the patient tried and failed, defined as uncontrolled symptoms, with either of the following treatments:</p> <ul style="list-style-type: none"> • LAMA/LABA (Bevespi Aerosphere, Stiolto Respimat, Anoro Ellipta) OR • LAMA/LABA/ICS (Breztri Aerosphere, Trelegy Ellipta)? 	<p><input type="checkbox"/> Yes Proceed to question 8</p>	<p><input type="checkbox"/> No STOP Coverage not approved</p>
<p>8. Will the requested medication only be used as add on therapy to LAMA/LABA or LAMA/LABA/ICS?</p>	<p><input type="checkbox"/> Yes Sign and date below</p>	<p><input type="checkbox"/> No STOP Coverage not approved</p>

Step I certify the above is true to the best of my knowledge. Please sign and date:

3

Prescriber Signature

Date

[12 February 2025]